Annilea Gunn, MD
Family Medicine · Tampa, FLNPI 1043286479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $960 and has fallen 95.3% since, to $45 in 2025.
Across 133 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$281
- AbbVie$275
- Pfizer$261
- Novo Nordisk$241
- Amarin Pharma, Inc.$149
- Lilly USA, LLC$139
- plus $855 from 20 others
What the payments were for
- Food & beverage$2,14597%
- Education$563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $281 |
| AbbVie(2 entities) | 16 | $275 |
| Pfizer | 19 | $261 |
| Novo Nordisk | 15 | $241 |
| Amarin Pharma, Inc. | 9 | $149 |
| Lilly USA, LLC | 9 | $139 |
| Boehringer Ingelheim | 6 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| AstraZeneca | 4 | $63 |
| Abbott | 3 | $53 |
| Johnson & Johnson | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Novartis | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| GSK | 2 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Mimedx Group, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Cashflow Solutions, LLC | 1 | $21 |
| Gilead | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $11 |
How this compares
$2,201 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 12 | $2,171 |
| Atorvastatin Calcium | 11 | $365 |
| Carvedilol | 13 | $363 |
| Trazodone Hcl | 13 | $130 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Tampa
- Emily HornTampa$184K
- Mark SeldesTampa$36K
- Robert MirskyTampa$31K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.